Source-grounded facts extracted from IN8BIO, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IN8BIO, INC. terminated Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (effective 2026-05-29).
“On May 29, 2026, the Company and Cantor mutually agreed to terminate the Cantor Sales Agreement and the offering of shares contemplated thereby, effective at the close of business on May 29, 2026, pursuant to Sections 12(b) and 12(c) of the Cantor Sales Agreement.”
IN8BIO, INC. entered into Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC (effective 2026-06-01).
“On June 1, 2026, IN8bio, Inc. (the “ Company ”) entered into a Capital on Demand TM Sales Agreement (the “ Sales Agreement ”) with JonesTrading Institutional Services LLC (the “ Agent ”) with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares (the “ Placement Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”), through or to the Agent.”
IN8BIO, INC. shareholders approved Approval of the Amended and Restated 2026 Equity Incentive Plan at the 2026-05-07 meeting.
“Proposal No. 3 : Approval of the 2026 Plan. The 2026 Plan was approved. The votes were case as follows: Votes For Votes Against Abstained Broker Non-Votes Approval of the 2026 Plan 5,064,465 1,106,779.83 14,060 1,776,813.17”
IN8BIO, INC. shareholders approved Ratification of the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.
“Proposal No. 2 : Ratification of the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of CohnReznick LLP 7,898,219.83 8,644.17 55,254”
IN8BIO, INC. shareholders approved Election of two nominees to serve as Class II directors at the 2026-05-07 meeting.
“Proposal No. 1 : Election of two nominees to serve as Class II directors, each to serve until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. All nominees were elected. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Peter Brandt 5,206,187.67 979,117.17 1,776,813.17 Corinne Epperly 6,143,941.67 41,363.17 1,776,813.17”
IN8BIO, INC. reported the first quarter ended March 31, 2026 results: net income a net loss of $5.1 million, or $0.26 per basic and diluted common share, EPS $0.26 per basic and diluted common share.
“The Company reported a net loss of $5.1 million, or $0.26 per basic and diluted common share, for the three months ended March 31, 2026, compared with a net loss of $5.6 million, or $2.16 per basic and diluted common share, for the comparable prior year period.”
IN8BIO, INC. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025.”
IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the "Investors") valued at aggregate gross proceeds of approximately $20.1 million (effective 2025-12-18).
“On December 18, 2025, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”)”
IN8BIO, INC. issued Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant of warrant to the Investors for aggregate gross proceeds of approximately $20.1 million.
“At the Initial Closing, the Company has agreed to issue and sell to the Investors an aggregate of 5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share (the “Share Price”), and, in lieu of Common Stock, Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant (the “Pre-Funded Warrant Price”) for aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses.”
IN8BIO, INC. issued 5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share of common stock to the Investors for aggregate gross proceeds of approximately $20.1 million.
“to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant (the “Pre-Funded Warrant Price”) for aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses. Pursuant to the Purchase Agreement, subject to the occurrence of the Second Closing Trigger (as”
Travis Whitfill resigned as Director at IN8BIO, INC..
“On March 4, 2025, Travis Whitfill notified the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) of his resignation from the Board and its committees, effective as of May 9, 2025.”
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until August 4, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the Nasdaq Capi”
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Com”
Trishna Goswami departed as Chief Medical Officer at IN8BIO, INC..
“On September 8, 2024, IN8bio, Inc. (the “Company”) and Trishna Goswami, M.D., the Company’s Chief Medical Officer, reached the mutual decision to have Dr. Goswami step down as Chief Medical Officer, effective September 6, 2024.”
IN8BIO, INC. announced a restructuring with charges of approximately $0.3 million affecting all functional areas, New York City and Birmingham, Alabama sites (from 37 to 19 full-time employees).
“such employee’s execution of a separation agreement, which includes a general release of claims against the Company. The Company expects to incur one-time costs of approximately $0.3 million in connection with this workforce reduction, of which nearly all are cash expenditures related to severance. The Company communicated the workforce reduction on September 4, 2024”
IN8BIO, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023, EPS $0.22 per basic and diluted common share.
“IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
IN8BIO, INC. entered into Registration Rights Agreement with the Investors (effective 2023-12-11).
“Also on December 11, 2023, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register for resale the Shares and the Common Stock underlying the Warrants”
IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the Investors) valued at $14.4 million (effective 2023-12-11).
“On December 11, 2023, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 11,823,829 units (the “Units”)”
IN8BIO, INC.: Board approved and adopted Second Amended and Restated Bylaws with changes addressing universal proxy rules, advance notice requirements, and other updates (effective 2023-12-06).
“On December 6, 2023, the Board approved and adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), which became effective immediately.”
Corinne Epperly was appointed as Class II Director at IN8BIO, INC..
“appointed Corinne Epperly, M.D., as a Class II director of the Company”
IN8BIO, INC. reported the three months ended September 30, 2023 results: net income Net loss of $7.2 million, or $0.23 per basic and diluted common share, EPS $0.23 per basic and diluted common share.
“The Company reported a net loss of $7.2 million, or $0.23 per basic and diluted common share, for the three months ended September 30, 2023”
IN8BIO, INC. reported the quarter ended June 30, 2023 results: net income $7.7 million, EPS $0.27 per basic and diluted common share.
“IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the second quarter ended June 30, 2023.”
IN8BIO, INC. shareholders approved Ratification of the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-15 meeting.
“Proposal No. 3 : Ratification of the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023.”
IN8BIO, INC. shareholders approved Ratification of the Amended and Restated 2023 Equity Incentive Plan (the "2023 Plan"). at the 2023-06-15 meeting.
“Proposal No. 2 : Ratification of the Amended and Restated 2023 Equity Incentive Plan (the " 2023 Plan ").”
IN8BIO, INC. shareholders approved Election of two nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-15 meeting.
“Proposal No. 1 : Election of two nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified.”
IN8BIO, INC. reported first quarter ended March 31, 2023 results: net income $7.5 million, EPS $0.30 per basic and diluted common share.
“The Company reported a net loss of $7.5 million, or $0.30 per basic and diluted common share, for the three months ended March 31, 2023”
Jeremy Graff, Ph.D. was appointed as Class I director at IN8BIO, INC..
“appointed Jeremy Graff, Ph.D., as a Class I director of the Company”
IN8BIO, INC. reported financial results for the fourth quarter and full-year ended December 31, 2022.
“On March 30, 2023, IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
IN8BIO, INC. reported the third quarter ended September 30, 2022 results: revenue $27.6 million, net income $7.4 million, or $0.34 per basic and diluted common share, EPS $0.34 per basic and diluted common share.
“of Louisville as the GMP manufacturing center for INB-400. • Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022. NEW YORK, Nov. 10, 2022 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T”
Kate Rochlin was appointed as Chief Operating Officer at IN8BIO, INC..
“announced that the Board of Directors had appointed Kate Rochlin, Ph.D. as the Company’s Chief Operating Officer, effective as of December 1, 2021.”
Trishna Goswami was appointed as Chief Medical Officer at IN8BIO, INC..
“Effective as of November 15, 2021, IN8bio, Inc. (the “ Company ”) appointed Dr. Trishna Goswami as the Company’s Chief Medical Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.